|
|
Volumn 91, Issue 2, 1999, Pages 111-
|
|
How should HER2 status be determined?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ARTICLE;
BREAST TUMOR;
CHEMISTRY;
CLINICAL TRIAL;
FEMALE;
HUMAN;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DOXORUBICIN;
FEMALE;
HUMANS;
RECEPTOR, ERBB-2;
TREATMENT OUTCOME;
|
|
EID: 0033585282
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/91.2.111 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|
